stockrowAytu BioPharma, Inc.
AYTUHealthcare Drug Manufacturers Specialty & Generic
Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025.
- Revenue
- +6.42%
- EPS
- +100.0%
- Free cash flow
- +57.7%
- Total debt
- −21.9%
Quarter to June 2026, against a year earlier
Follow AYTU
Alert me
Aytu BioPharma, Inc. (AYTU) Return on invested capital
Aytu BioPharma, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −20.0%. Over the past ten years it has ranged from −1,370.6% (fiscal 2016) to 0.00% (fiscal 2019); the current reading is higher than 83% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2026 | −20.0% | 29.78 |
| FY2025 | −49.8% | (45.42) |
| FY2024 | −4.35% | 28.23 |
| FY2023 | −32.6% | 126.66 |
| FY2022 | −159.2% | (126.52) |
| FY2021 | −32.7% | (11.13) |
| FY2020 | −21.6% | (21.59) |
| FY2019 | 0.00% | 195.07 |
| FY2018 | −195.1% | 207.78 |
| FY2017 | −402.9% | 967.79 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| IXHL Incannex Healthcare Inc. compare | 0.00% |
| OPTH Optimi Health Corp. compare | 0.00% |
| CPHI China Pharma Holdings, Inc. compare | −7.23% |
| TXMD TherapeuticsMD, Inc. compare | −13.8% |
| RMTI Rockwell Medical, Inc. compare | −14.6% |
| AYTU Aytu BioPharma, Inc. | −20.0% |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | −36.7% |
| BFRI Biofrontera Inc. compare | −69.5% |
| SCYX SCYNEXIS, Inc. compare | −110.7% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)